(TheNewswire)
LONDON, ON - TheNewswire – November 16 ,2021 -- SernovaCorp . (TSXV:SVA)(FSE/XETRA:PSH)(OTC:SEOVF), aleading clinical-stage company focused on regenerative medicinetherapeutics, today announced that Dr. Philip Toleikis, President andCEO, will present at the Canaccord Genuity Virtual MedTech,Diagnostics and Digital Health & Services Forum on Thursday,November 18 th , 2021 at 10:00am ET.
Management will be available throughout the conferencefor virtual one-on-one meetings. Investors interested in arranging ameeting with the Company’s management during the conference shouldcontact the Canaccord Genuity conference coordinator or Sernovainvestor relations.
Webcast Information:
A live webcast of Sernova’s presentation session willbe available under ‘Featured News’ on the Company’s websiteat https://www.sernova.com/press or by accessing the event directly at following link: https://wsw.com/webcast/canaccord61/sva.v/2570694 .
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing an implantable medical device and immune protected therapeuticcells (i.e. human donor cells, corrected human cells and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASE CONTACT:
investor.relations@sernova.com
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events, including results of clinical trials, andare based on information currently available to management on the datesuch statements were made. Many factors could cause Sernova’s actualresults, performances, or achievements to not be as anticipated,estimated or intended or to differ materially from those expressed orimplied by the forward-looking statements contained in this newsrelease. Many of the factors are beyond our control, including thosecaused by, related to, or impacted by the novel coronavirus pandemic.Investors should consult the company’s quarterly and annual filingsavailable on www.sedar.com for additional information on risks and uncertainties relating to theforward-looking statements. Sernova expressly disclaims any intentionor obligation to update or revise any forward-looking statements,whether as a result of new information, future events orotherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.